140 related articles for article (PubMed ID: 20540879)
21. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.
Irwin DE; Kopp ZS; Agatep B; Milsom I; Abrams P
BJU Int; 2011 Oct; 108(7):1132-8. PubMed ID: 21231991
[TBL] [Abstract][Full Text] [Related]
22. Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women.
Honjo H; Kawauchi A; Ukimura O; Nakao M; Kitakoji H; Miki T
Neurourol Urodyn; 2009; 28(8):982-5. PubMed ID: 19267392
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries.
Sykes D; Castro R; Pons ME; Hampel C; Hunskaar S; Papanicolaou S; Quail D; Samsioe G; Voss S; Wagg A; Monz BU
Maturitas; 2005 Nov; 52 Suppl 2():S13-23. PubMed ID: 16297580
[TBL] [Abstract][Full Text] [Related]
24. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
[TBL] [Abstract][Full Text] [Related]
25. Nocturia in patients with overactive bladder.
Espuña-Pons M; Blasco P; Pérez M; Rebollo P
Arch Esp Urol; 2010 Jun; 63(5):363-72. PubMed ID: 20587841
[TBL] [Abstract][Full Text] [Related]
26. Predictors of variability in urinary incontinence and overactive bladder symptoms.
Stewart WF; Minassian VA; Hirsch AG; Kolodner K; Fitzgerald M; Burgio K; Cundiff GW; Blaivas J; Newman D; Lerch VR; Dilley A
Neurourol Urodyn; 2010 Mar; 29(3):328-35. PubMed ID: 19693956
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
28. The prevalence of overactive bladder.
Milsom I; Stewart W; Thüroff J
Am J Manag Care; 2000 Jul; 6(11 Suppl):S565-73. PubMed ID: 11183899
[TBL] [Abstract][Full Text] [Related]
29. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years.
Malmsten UG; Molander U; Peeker R; Irwin DE; Milsom I
Eur Urol; 2010 Jul; 58(1):149-56. PubMed ID: 20356669
[TBL] [Abstract][Full Text] [Related]
30. Costs of urinary incontinence and overactive bladder in the United States: a comparative study.
Hu TW; Wagner TH; Bentkover JD; Leblanc K; Zhou SZ; Hunt T
Urology; 2004 Mar; 63(3):461-5. PubMed ID: 15028438
[TBL] [Abstract][Full Text] [Related]
31. Urinary incontinence and overactive bladder in patients with heart failure.
Palmer MH; Hardin SR; Behrend C; Collins SK; Madigan CK; Carlson JR
J Urol; 2009 Jul; 182(1):196-202. PubMed ID: 19447424
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and impact on generic quality of life of urinary incontinence in Japanese working women: assessment by ICI questionnaire and SF-36 Health Survey.
Araki I; Beppu M; Kajiwara M; Mikami Y; Zakoji H; Fukasawa M; Takeda M
Urology; 2005 Jul; 66(1):88-93. PubMed ID: 15992871
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
34. [Urinary incontinence: frequency and diagnostic and therapeutic approach in general practice in Italy].
Parazzini F; Cipriani S; de'Besi P; Lavezzari M; Artibani W;
Arch Ital Urol Androl; 2001 Sep; 73(3):160-7. PubMed ID: 11822061
[TBL] [Abstract][Full Text] [Related]
35. Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review.
Irwin DE; Milsom I; Chancellor MB; Kopp Z; Guan Z
Eur Urol; 2010 Oct; 58(4):532-43. PubMed ID: 20573443
[TBL] [Abstract][Full Text] [Related]
36. The economic impact of overactive bladder syndrome in six Western countries.
Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
[TBL] [Abstract][Full Text] [Related]
37. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries.
Irwin DE; Milsom I; Kopp Z; Abrams P; Cardozo L
BJU Int; 2006 Jan; 97(1):96-100. PubMed ID: 16336336
[TBL] [Abstract][Full Text] [Related]
38. Clinical Burden and Nonpharmacologic Management of Nursing Facility Residents with Overactive Bladder and/or Urinary Incontinence.
Zarowitz BJ; Allen C; O'Shea T; Tangalos E; Berner T; Ouslander JG
Consult Pharm; 2015 Sep; 30(9):533-42. PubMed ID: 26350894
[TBL] [Abstract][Full Text] [Related]
39. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?
Van Brummen HJ; Bruinse HW; Van de Pol G; Heintz AP; Van der Vaart CH
BJU Int; 2006 Feb; 97(2):296-300. PubMed ID: 16430633
[TBL] [Abstract][Full Text] [Related]
40. The prevalence of overactive bladder syndrome and urinary incontinence in a Turkish women population; associated risk factors and effect on Quality of life.
Sarici H; Ozgur BC; Telli O; Doluoglu OG; Eroglu M; Bozkurt S
Urologia; 2016 May; 83(2):93-8. PubMed ID: 24803353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
